Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway

Brain Research

Volumn 710, Issue 1-2, 1996, Pages 143-149

  Baltuch, Gordon H ^a   Yong, Voon Wee ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Glioma; Inhibitor; Protein kinase C; Signal transduction; Tyrosine kinase

Indexed keywords

GENISTEIN; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0029882168     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(95)01395-4     Document Type: Article

References (46)

1. Ahmad, S., Mineta, T., Martuza, R.L. and Glazer, R.I., Antisense expression of protein kinase Ca inhibits the growth and tumorigenicity of human glioblastoma cells, Neurosurgery, 35 (1994) 904-909.
2. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M. and Fukami, Y., Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem., 262 (1987) 5592-5595.
3. Alterman, R.L. and Kornblith, P.K., Glioma biology: basic science with implications for current and future therapy. In M.L.J. Apuzzo (Ed.), Neurosurgical Topics: Malignant Cerebral Glioma, Park Ridge, III: AANS Publications Committee, 1990, pp. 25-40.
4. Baltuch, G.H., Couldwell, W.T., Villemure, J.G. and Yong, V.W., Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen, Neurosurgery, 33 (1993) 495-501.
5. Baltuch, G.H., Dooley, N.P., Couldwell, W.T. and Yong, V.W., Staurosporine differentially inhibits glioma versus non-glioma cell lines, J. Neuro-Oncol., 16 (1993) 141-147.
6. Baltuch, G.H., Shenouda, G., Langleben, A. and Villemure, J.G., High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression, Can. J. Neurol. Sci., 20 (1993) 168-170.
7. Baltuch, G.H., Dooley, N.P., Rostworowski, K.M., Villemure, J.G. and Yong, V.W., Protein kinase C isoform α in C6 glioma cells and its role in cell proliferation, J. Neuro-Oncol., 24 (1995) 241-250.
8. Basu, A., The potential of protein kinase C as a target for anticancer treatment, Pharmac. Ther., 59 (1993) 257-280.
9. Benzil, D.L., Finkelstein, S.D., Epstein, M.H. and Finch, P.W., Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression, Cancer Res., 52 (1992) 2951-2956.
10. Cacace, A.M., Guadagno, S.N., Krauss, R.S., Fabbro, D. and Weinstein, I.B., The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts, Oncogene, 8 (1993) 2095-2104.
11. Cantley, L.C., Auger, K.R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R. and Soltoff, S., Oncogenes and signal signal transduction, Cell, 64 (1991) 281-302.
12. Collins, V.P., Cultured human glial and glioma cells, Int. Rev. Exp. Pathol., 24 (1982) 135-192.
13. Coughlin, S.R., Lee, W.M.F., Williams, P.W., Giels, G.M. and Williams, L.T., c-myc gene expression is stimulated by agents that activate protein kinase C and does not account for the mitogenic effect of PDGF, Cell, 43 (1985) 243-251.
14. Couldwell, W.T., Uhm, J.H., Antel, J.P. and Yong, V.W., Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro, Neurosurgery, 29 (1991) 880-887.
15. Couldwell, W.T., Antel, J.P. and Yong, V.W., Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C, Neurosurgery, 31 (1992) 717-724.
16. Couldwell, W.T., Weiss, M.H., DeGiorgio, C.M., Weiner, L.P., Hinton, D.R., Ehresmann, G.R., Conti, P.S. and Apuzzo, M.L.J., Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen, Neurosurgery, 32 (1993) 485-490.
17. Couldwell, W.T., Gopalakrishna, R., Hinton, D.R., He, S., Weiss, M.H., Law, R.E. and Apuzzo, M.L.J., Hypericin: a potential antiglioma therapy, Neurosurgery, 35 (1994) 705-710.
18. Couldwell, W.T., Hinton, D.R., He, S., Chen, T.C., Sebat, I., Weiss, M.H. and Law, R.E., Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines, FEBS Lett. 354 (1994) 43-46.
19. Dekker, L.V. and Parker, P.J., Protein kinase C - a question of specificity, Trends Biochem., 19 (1994) 73-77.
20. Delage, S., Chastre, E., Empereur, S., Wicek, D., Veissiére, D., Capeau, J., Gespach, C. and Cherqui, G., Increased protein kinase C α expression in human colonie Caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes, Cancer Res. 53 (1993) 2762-2770.
21. Fleischman, L.F., Chahwala, S.B. and Cantley, L., Ras-transformed cells: altered levels of phosphatidylinositol-4,5-bisphosphate and catabolites, Science, 231 (1986) 407-410.
22. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A. and Cawthon, R.M., p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression, Cancer Res. 52 (1992) 674-679.
23. cdc2 kinases, Biochem. Biophys. Res. Commun., 184 (1992) 80-85.
24. 3H]-staurosporine on various protein kinases, Biochem. Biophys. Res. Commun., 171 (1990) 189-195.
25. Huang, M., Chida, K., Kamata, N., Nose, K., Kato, M., Homma, Y., Takenawa, T. and Kuroki, T., Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts, J. Biol. Chem., 263 (1988) 17975-17980.
26. Hug, H. and Sarre, T.F., Protein kinase C isoenzymes: divergence in signal transduction, Biochem. J. 291 (1993) 329-343.
27. Langleban, A., Preul, M., Tampieri, D., Tsatoumas, A., Bahary, J.P., Shenouda, G., Baltuch, G.H. and Villemure, J.G., Combined hormonal and chemotherapy treatment of recurrent high grade astrocytoma, Proc. AACR, 1994 (Abstr.).
28. Maxwell, M., Naber, S.P., Wolfe, H.J., Galanopoulos, T., Hedley-White, E.T., Black, P.M.L. and Antoniades, H.N., Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance, J. Clin. Invest., 86 (1990) 131-140.
29. Meyer, T., Regenass, U., Fabbro, D., Alteri, E., Rösel, J., Müller, M., Caravatti, G. and Matter, M., A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int. J. Cancer, 43 (1989) 851-856.
30. Mischak, H., Goodnight, J., Kolch, W., Martiny-Baron, G., Schaechle, C., Kazanietz, M.G., Blumberg, P.M., Pierce, J.H., and Mushinski, J.F., Overexpression of protein kinase C-δ and -∈ in NIH 3T3 cells induce opposite effects on growth, morphology, anchorage dependence, and tumorigenecity, J. Biol. Chem., 268 (1993) 6090-6096.
31. Nister, M., Cklaesson-Welsh, L., Eriksson, A., Heldinm, C.H.J. and Westermark, B., Differential expression of platelet-derived growth factore receptors in human malignant glioma cell lines, J. Biol. Chem., 266 (1991) 16755-16763.
32. Nister, M., Liberman, T.A., Betsholtz, C., Paterson, M., Claesson-Welsh, L., Heldin, C.H., Schlessinger, J. and Westermark, B., Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines, Cancer Res., 48 (1988) 3910-3918.
33. Pollack, I.F., Randall, M.S., Kristofik, M.P., Kelly, R.H., Selker, R.G. and Vertosick Jr., F.T., Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways, J. Neurosurg., 75 (1991) 284-293.
34. Pollack, I.F., Randall, M.S., Kristofik, M.P., Kelly, R.H., Selker, R.G. and Vertosick Jr. F.T., Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro, Cancer Res., 50 (1990) 7134-7138.
35. Reifenberger, G., Deckert, M. and Wechsler, W., Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors, Acta Neuropathol., 78 (1989) 166-175.
36. Ruegg, U.T. and Burgess, G.M., Staurosporine, K-252 and UCN-01: potent but non-specific inhibitors of protein kinases, Trends Pharmacol. Sci., 10 (1989) 218-220.
37. Russell, L. and Rubinstein, L.J., Pathology of Tumours of the Nervous System, Arnold, London, 1989.
38. Secrist, J.P., Sehgal, I., Powis, G. and Abraham, R.T., Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine, J. Biol. Chem., 265 (1990) 20394-20400.
39. Sidransky, D., Mikkelsen, T., Schwechleimer, K., Rosenblum, M.L., Cavanee, W. and Vogelstein, B., Clonal expression of p53 mutant cells is associated with brain tumor progression, Nature, 355 (1992) 846-847.
40. ++ dependent protein kinase, Biochem. Biophys. Res. Comm., 135 (1986) 397-402.
41. Tanaka, C. and Nishizuka, Y., The protein kinase C family for neuronal signalling, Ann. Rev. Neurosci., 17 (1994) 551-567.
42. Tondo, T., Shitara, N., Nakamura, H., Takakura, K. and Ikeda, K., Immunohistochemical demonstration of protein kinase C isozymes in human brain tumors, Neurosurgery, 29 (1991) 399-404.
43. Vertosik, F.T., Selker, R.G., Pollack, I.F. and Arena, V., The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy. Preliminary results in a series of 'failed' patients, Neurosurgery, 30 (1992) 897-903.
44. Von Deimling, A., Eibl, R.H., Ohgaki, H., Louis, D.N., Von Ammon, K., Petersen, I., Kleihues, P., Chung, R.Y., Wiestler, O.D. and Seizinger, B.R., p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma, Cancer Res., 52 (1992) 2987-2990.
45. Weinstein, I.B., The role of protein kinase C in growth control and the concept of carcinogenesis as a progressive disorder in signal transduction. In Y. Nishizuka et al. (Eds.), Advances in Second Messenger and Phosphoprotein Research, Vol. 24, Raven Press, New York, 1990, pp. 307-316.
46. Westphal, M. and Herrmann, H.D., Growth factor biology and oncogene activation in human gliomas and their implication for specific therapeutic consequences, Neurosurgery, 25 (1989) 681-694.